Atwater Malick’s bluebird bio BLUE Stock Holding History

Atwater Malick’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-8	Closed	-$10K	–	60
2019 Q3	$10K	Buy	+8	New	+$12.2K	0.01%	135

Other funds holding BLUE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atwater Malick's BLUE Position: Q4 2019 in Review

Atwater Malick sold out of bluebird bio (BLUE) in Q4 2019, closing a stake of 8 shares — an estimated $10K sold.

Atwater Malick first reported a position in BLUE in Q3 2019 and held it in 1 quarter. The position peaked at $10K in Q3 2019. 274 funds tracked by Wall St. Rank hold BLUE as of Q4 2019.

Atwater Malick reported no remaining bluebird bio position as of Q4 2019 after selling out during the quarter.
Atwater Malick sold 8 bluebird bio shares in Q4 2019, an estimated $10K.
Atwater Malick first reported a position in bluebird bio in Q3 2019 and held it in 1 quarter.
Atwater Malick's bluebird bio position peaked at $10K in Q3 2019.
274 funds tracked by Wall St. Rank held bluebird bio as of Q4 2019.

Based on Atwater Malick's 13F filing for Q4 2019, filed 7 Jan 2020.